Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. (öffnet neues Fenster)

Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ.

Quelle‎: Cancer 2014;120(2):222-8.

Indiziert‎: PubMed 24122387

DOI‎: 10.1002/cncr.28405

https://www.ncbi.nlm.nih.gov/pubmed/24122387 (öffnet neues Fenster)

Autologous stem-cell transplantation can be performed safely without the use of blood-product support. (öffnet neues Fenster)

Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA.

Quelle‎: J Clin Oncol 2004;22(20):4087-94.

Indiziert‎: PubMed 15353543

DOI‎: 10.1200/JCO.2004.01.144

https://www.ncbi.nlm.nih.gov/pubmed/15353543 (öffnet neues Fenster)

Leucemia aguda en los Testigos de Jehová. [Acute leukemia in Jehovah's Witnesses.] [Spanish] (öffnet neues Fenster)

Bueno J, Zuazu J, Villalba T, Julià A.

Quelle‎: Sangre (Barc) 1999;44(5):381-2.

Indiziert‎: PubMed 10618916

https://www.ncbi.nlm.nih.gov/pubmed/10618916 (öffnet neues Fenster)

The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products. (öffnet neues Fenster)

Ciurea S, Beri R, Dobogai L, Chunduri S, Mahmud N, Rondelli D, Peace D.

Quelle‎: Bone Marrow Transplant 2006;37(3):325-7.

Indiziert‎: PubMed 16314850

DOI‎: 10.1038/sj.bmt.1705223

https://www.ncbi.nlm.nih.gov/pubmed/16314850 (öffnet neues Fenster)

Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia. (öffnet neues Fenster)

Cogle CR, Scott BL, Boyd T, Garcia-Manero G.

Quelle‎: Oncologist 2015;20(12):1404-12.

Indiziert‎: PubMed 26463870

DOI‎: 10.1634/theoncologist.2015-0165

https://www.ncbi.nlm.nih.gov/pubmed/26463870 (öffnet neues Fenster)

Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. (öffnet neues Fenster)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Quelle‎: Leuk Res 2011;35(8):991-7.

Indiziert‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (öffnet neues Fenster)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (öffnet neues Fenster)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Quelle‎: Br J Haematol 2014;165(4):497-503.

Indiziert‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (öffnet neues Fenster)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (öffnet neues Fenster)

Dainer PM, Knupp CL, Sartiano GP.

Quelle‎: Am J Hematol 1992;40(2):156-7.

Indiziert‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (öffnet neues Fenster)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (öffnet neues Fenster)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Quelle‎: Lancet Oncol 2013;14(6):525-33.

Indiziert‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (öffnet neues Fenster)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (öffnet neues Fenster)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Quelle‎: N Engl J Med 2020;383(7):617-29.

Indiziert‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (öffnet neues Fenster)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (öffnet neues Fenster)

El Chaer F, Ballen KK

Quelle‎: Br J Haematol 2020;190(5):696-707.

Indiziert‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (öffnet neues Fenster)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (öffnet neues Fenster)

Emadi A, Bade NA, Stevenson B, Singh Z.

Quelle‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Indiziert‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (öffnet neues Fenster)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (öffnet neues Fenster)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Quelle‎: J Clin Oncol 2009;27(28):4733-40.

Indiziert‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (öffnet neues Fenster)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (öffnet neues Fenster)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Quelle‎: Int J Hematol 1997;65(4):415-6.

Indiziert‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (öffnet neues Fenster)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (öffnet neues Fenster)

Garelius H, Grund S, Stockelberg D.

Quelle‎: Clin Case Rep 2015;3(5):287-90.

Indiziert‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (öffnet neues Fenster)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (öffnet neues Fenster)

Juliusson G.

Quelle‎: Am J Hematol 1996;53(1):49.

Indiziert‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (öffnet neues Fenster)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (öffnet neues Fenster)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Quelle‎: Eur J Haematol 2004;72(4):264-7.

Indiziert‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (öffnet neues Fenster)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (öffnet neues Fenster)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Quelle‎: Am J Hematol 1996;51(3):251-2.

Indiziert‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (öffnet neues Fenster)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (öffnet neues Fenster)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Quelle‎: Hematol Oncol 2014;32(1):40-6.

Indiziert‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (öffnet neues Fenster)

Cytarabine dose for acute myeloid leukemia. (öffnet neues Fenster)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Quelle‎: N Engl J Med 2011;364(11):1027-36.

Indiziert‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (öffnet neues Fenster)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (öffnet neues Fenster)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Quelle‎: Bone Marrow Transplant 2003;32(4):433-6.

Indiziert‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (öffnet neues Fenster)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (öffnet neues Fenster)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Quelle‎: N Engl J Med. 2022;386(16):1519-31. 

Indiziert‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (öffnet neues Fenster)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (öffnet neues Fenster)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Quelle‎: Gynecol Oncol 2012;124(2):221-4.

Indiziert‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (öffnet neues Fenster)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (öffnet neues Fenster)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Quelle‎: Leuk Res Rep. 2022 25;18:100355.

Indiziert‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (öffnet neues Fenster)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (öffnet neues Fenster)

Norfolk DR, Wade P, Carter R.

Quelle‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (öffnet neues Fenster)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (öffnet neues Fenster)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Quelle‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indiziert‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (öffnet neues Fenster)

Hematopoietic growth factors: personalization of risks and benefits. (öffnet neues Fenster)

Puhalla S, Bhattacharya S, Davidson NE.

Quelle‎: Mol Oncol 2012;6(2):237-41.

Indiziert‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (öffnet neues Fenster)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (öffnet neues Fenster)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Quelle‎: Leuk Lymphoma 2021;62(6):1497-501.

Indiziert‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (öffnet neues Fenster)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (öffnet neues Fenster)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Quelle‎: Blood 2020;135(7):463-71.

Indiziert‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (öffnet neues Fenster)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (öffnet neues Fenster)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Quelle‎: Bone Marrow Transplant 2005;36(8):715-20.

Indiziert‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (öffnet neues Fenster)

A Mexican way to cope with stem cell grafting. (öffnet neues Fenster)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Quelle‎: Hematology 2012;17 Suppl 1:S195-7.

Indiziert‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (öffnet neues Fenster)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (öffnet neues Fenster)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Quelle‎: Blood 2009;113(9):1875-91.

Indiziert‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (öffnet neues Fenster)

SCT in Jehovah's Witnesses: the bloodless transplant. (öffnet neues Fenster)

Sloan JM, Ballen K.

Quelle‎: Bone Marrow Transplant 2008;41(10):837-44.

Indiziert‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (öffnet neues Fenster)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (öffnet neues Fenster)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Quelle‎: Cancer 2006;107(8):1839-43.

Indiziert‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (öffnet neues Fenster)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (öffnet neues Fenster)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Quelle‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Indiziert‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (öffnet neues Fenster)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (öffnet neues Fenster)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Quelle‎: Onco Targets Ther 2013;7:13-21.

Indiziert‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (öffnet neues Fenster)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (öffnet neues Fenster)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Quelle‎: J Clin Oncol 2007;25(30):4722-9.

Indiziert‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (öffnet neues Fenster)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (öffnet neues Fenster)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Quelle‎: Blood 2020;135(24):2137-45.

Indiziert‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (öffnet neues Fenster)

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. (öffnet neues Fenster)

Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R.

Quelle‎: Blood 2001;98(13):3584-8.

Indiziert‎: PubMed 11739160

https://www.ncbi.nlm.nih.gov/pubmed/11739160 (öffnet neues Fenster)

A Jehovah's Witness with acute myeloid leukemia successfully treated with an epigenetic drug, azacitidine: a clue for development of anti-AML therapy requiring minimum blood transfusions. (öffnet neues Fenster)

Yamamoto Y, Kawashima A, Kashiwagi E, Ogata K.

Quelle‎: Case Rep Hematol 2014;2014:141260.

Indiziert‎: PubMed 25371835

DOI‎: 10.1155/2014/141260

https://www.ncbi.nlm.nih.gov/pubmed/25371835 (öffnet neues Fenster)

Acute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma. (öffnet neues Fenster)

Zhou L, Mohsen A, Khan MA, Guthrie T.

Quelle‎: J Chemother 2014;26(3):184-6.

Indiziert‎: PubMed 24621157

DOI‎: 10.1179/1973947813Y.0000000130

https://www.ncbi.nlm.nih.gov/pubmed/24621157 (öffnet neues Fenster)

Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. (öffnet neues Fenster)

Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ.

Quelle‎: J Clin Oncol 2013;31(33):4215-21.

Indiziert‎: PubMed 24127444

DOI‎: 10.1200/JCO.2013.48.8312

https://www.ncbi.nlm.nih.gov/pubmed/24127444 (öffnet neues Fenster)